[ET Net News Agency, 27 October 2021] Innovent Biologics, Inc. (01801) said in the
third quarter of 2021, the revenue attributable to sales of TYVYT (sintilimab injection)
was around RMB800 million.
It has kept achieving encouraging performance with continuous quarter over quarter
growth trend on the sales volume. (RC)